<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934800</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0070</org_study_id>
    <nct_id>NCT04934800</nct_id>
  </id_info>
  <brief_title>Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)</brief_title>
  <official_title>Oral CLADribine in Patients That Change From First-line Disease Modifying Treatments for Multiple Sclerosis: a pROspective effectivenesS and Safety Study (CLAD CROSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Hellas sa., Greece, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim is to study in the real world setting the effectiveness of Cladribine tablets in&#xD;
      terms of Annualized Relapse Rate (ARR) and disability progression, in participants who&#xD;
      switched from a first line Disease Modifying Drug (DMD) (Interferons, Glatiramer Acetate,&#xD;
      Teriflunomide, (Dymethyl fumarate) [DMF]) to treatment with Cladribine tablets in routine&#xD;
      clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">July 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period Over the 12 Months Period Before the End of Study Follow-Up</measure>
    <time_frame>12-months pre-baseline up to Year 2 post-baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period Over the 12 Months Period After the Start of Cladribine</measure>
    <time_frame>12-months pre-baseline up to Year 1 post-baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 6-Month Disability Progression in Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 6-Month Disability Progression in Timed 25 Foot Walk (T25FW)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 6-Month Disability Progression in 9-Hole-Peg Test (9HPT)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 6-Month Disability Improvement in Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 6-Month Disability Improvement in Timed 25 Foot Walk (T25FW)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 6-Month Disability Improvement in 9-Hole-Peg Test (9HPT)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessed by Multiple Sclerosis Impact Scale (MSIS-29)</measure>
    <time_frame>Baseline, Months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Assessed by Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM v1.4) Scale</measure>
    <time_frame>Months 6, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomic Data Assessed by Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Questionnaire</measure>
    <time_frame>Baseline, Months 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Adherence</measure>
    <time_frame>Up to Month 24</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.</description>
    <arm_group_label>Cladribine</arm_group_label>
    <other_name>MAVENCLAD ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a confirmed diagnosis of Highly Active Relapsing-Remitting Multiple&#xD;
        Sclerosis (RRMS).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with confirmed diagnosis of RRMS diagnosed by the treating physician&#xD;
             according to applicable clinical practice guidelines -(currently McDonald 2017&#xD;
             criteria), with high disease activity&#xD;
&#xD;
          -  Participants should have been treated with the same first-line DMD (Interferons,&#xD;
             Glatiramer Acetate, Teriflunomide, DMF) and at a stable dose for at least one year&#xD;
             prior to switch to Cladribine tablets and should have been prescribed Cladribine&#xD;
             tablets, according to the decision of the treating physician, prior to enrollment in&#xD;
             the study. Any washout period and/or washout methods required before switching (such&#xD;
             as elimination of Teriflunomide) must have been conducted, according to the decision&#xD;
             of the treating physician&#xD;
&#xD;
          -  Required history data should be available: Multiple Sclerosis (MS) data for the&#xD;
             12-months pre-baseline period (annualized relapse rate); MS Medication History (prior&#xD;
             DMDs)&#xD;
&#xD;
          -  Fulfilment of the criteria for treatment with Cladribine tablets per standard of care&#xD;
             in accordance with the local Summary of Product Characteristics (SmPC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to use of cladribine tablets according to the SmPC&#xD;
&#xD;
          -  Participants with history of alcohol or drug abuse that could potentially interfere&#xD;
             with their participation in the study&#xD;
&#xD;
          -  Participants that have received Cladribine in the past&#xD;
&#xD;
          -  Concurrent participation in an investigational study in which participant assessment&#xD;
             and/or treatment may be dictated by a protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KH der Barmherzige Brüder Eisenstadt - Neurology</name>
      <address>
        <city>Eisenstadt</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dr. Reinhard Krendl-Head</name>
      <address>
        <city>Sankt Veit an der Glan</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sozialmedizinisches Zentrum Baumgartner Höhe/Otto-Wagner-Spital Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Thrace, Medical School - Neurology Department</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>iiliop@med.duth.gr</email>
    </contact>
    <investigator>
      <last_name>Ioannis Iliopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>251 General Air Force Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dimitrisnaoumis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evangelos Kouremenos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>417 NIMITS Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>aiaspf@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Stouraitis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aeginiteion Hospital, University of Athens - A' Neurology Department</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>elisandread@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elissavet Andreadou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cvoumvou@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Voumvourakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelismos Hospital - Neurology Department</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>panodiangelo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Panagiotis Angelidakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genaral Hospital of Elefsina &quot;Thriasio&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>teresa_acquaviva@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tereza Aquaviva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sgatzon@med.uoa.gr</email>
    </contact>
    <investigator>
      <last_name>Stylianos Gatzonis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iatriko Athinon Clinic of Psychiko - Hematology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ntoskastr@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Triantafyllos Doskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ioannina - Neurology Department, Ioannina</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>skonitso@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Spyridon Konitsiotis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa - Rheumatology Clinic</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>edar@med.uth.gr</email>
    </contact>
    <investigator>
      <last_name>Efthymios Dardiotis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iatriko Palaioy Faliroy, Medical Center - Neurology Department</name>
      <address>
        <city>Paleo Faliro</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>d.papadopoulos@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Papadopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patra</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>echroni@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Chroni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Patra &quot;Agios Andreas&quot;</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>karanapana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Panagiotis Karanasios</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AHEPA General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>grigoria@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Grigoriadis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AHEPA General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>tsolakim1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Magda Tsolaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;G. Papanikolaou&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ubic1@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Sotirios Papagiannopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interbalkan Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>milonas@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Ioannis Mylonas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gderetzi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Georgia Deretzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Luke's Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>orologas@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Anastasios Orologas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII) - Dipartimento di Neurologia</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>msessa@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Maria Sessa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto G.Giglio di Cefalù - Neurologia-Centro Sclerosi Multipla</name>
      <address>
        <city>Cefalù</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>luigi.grimaldi@hsrgiglio.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Grimaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi G. D'Annunzio</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>valentina.tomassini@unich.it</email>
    </contact>
    <investigator>
      <last_name>Valentina Tomassini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Arcispedale Sant'Anna - Neurologia</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>l.caniatti@ospfe.it</email>
    </contact>
    <investigator>
      <last_name>Luisa M Caniatti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Foggia - Neurology</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>c.avolio@unifg.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Avolio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate) - Neurologia 2 - Sclerosi Multipla</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mauro.zaffaroni@asst-valleolona.it</email>
    </contact>
    <investigator>
      <last_name>Mauro Zaffaroni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL 1 Avezzano L'Aquila Sulmona- Ospedale Regionale San Salvatore - Dipartimento di Neurologia</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>rocco.totaro@univaq.it</email>
    </contact>
    <investigator>
      <last_name>Rocco Totaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca - S.C.Oncologia</name>
      <address>
        <city>Lucca</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gianluca.moscato@uslnordovest.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Moscato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro Neurolesi Bonino Pulejo - U.O. di Neurofisipatologia ed Ambulatori</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>edoardo.sessa@irccsme.it</email>
    </contact>
    <investigator>
      <last_name>Edoardo Sessa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli - U.O.S. Malattie Degenerative del S.N.C.</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gtmaniscalco@libero.it</email>
    </contact>
    <investigator>
      <last_name>Giorgia Teresa Maniscalco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della carità - Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>paola.naldi@maggioreosp.novara.it</email>
    </contact>
    <investigator>
      <last_name>Paola Naldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Regionale per la Sclerosi Multipla (CRESM) - SCDO Neurologia</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sclerosi.multipla@sanluigi.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Simona Malucchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone - Dipartimento di Neuroscienze</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>paolo.ragonese@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Ragonese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Udine Ospedale S. Maria della Misericordia - UO Neurologia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>massimiliano.difilippo@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Massimiliano Di Filippo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano &quot;Bianchi Melacrino Morelli - Centro Regionale Epilessia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>u.aguglia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Umberto Aguglia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Filippo Neri - Neurologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>elisabetta.ferraro@aslroma1.it</email>
    </contact>
    <investigator>
      <last_name>Elisabetta Ferraro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza - Dip. di Neurologia e Psichiatria (servizio EMG)</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>antonella.conte@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Antonella Conte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. U. San Giovanni Di Dio e Ruggi D'Aragona - Struttura Complessa di Oculistica</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mariadigregorio82@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Di Gregorio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) - D.U.Neurologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alberto.gajofatto@univr.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Gajofatto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF Drammen Sykehus - former Sykehuset Buskerud</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>line.broch@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Line Broch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset Namsos</name>
      <address>
        <city>Namsos</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>stephan.schuler@helse-nordtrondelag.no</email>
    </contact>
    <investigator>
      <last_name>Stephan Schüler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF - Ullevål</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>elgu@uus.no</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Celius</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku - Dept of Neurology</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alakul@umb.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Alina Kulakowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. L.Rydygiera w Krakowie - Neurology Department</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nowak.medical@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Ryszard Nowak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie - Uniwersytet Jagiellonski Collegium Medicum</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>slowik@cm-uj.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Agnieszka Slowik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu - Dept of Neurology</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>wkozubski@ump.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Kozubski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pomorski Uniwersytet Medyczny - Klinika Neurologii</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>marta.masztalewicz@pum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Marta Masztalewicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny - Dept of Neurology</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>beata.zakrzewska@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Beata Zakrzewska-Pniewska Zakrzewska-Pniewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny - Klinika Neurologiczna</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>astepien@wim.mil.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Stepien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku</name>
      <address>
        <city>Zory</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>maciejswiat@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maciej Swiat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Ocidental, E.P.E. - Hospital de Egas Moniz - Serviço de Neurologia</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>anasofia.correia@ulsm.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Ana Sofia Correia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano) - Serviço de Neurologia</name>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>filipemajo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Filipe Correia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João, E.P.E. - Serviço de Neurologia</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>teresamendonca.neuro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Mendonça</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta, EPE - Serviço de Neurologia</name>
      <address>
        <city>Pragal</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>maria.irene.mendes@hgo.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Irene Mendes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Setubal, EPE - Hospital São Bernardo</name>
      <address>
        <city>Setúbal</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>rpguerreiro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rui Guerreiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saúde do Alto Minho, EPE - Serviço de Neurologia</name>
      <address>
        <city>Viana De Castelo</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sandra.perdigao@ulsam.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Sandra Perdigão</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital - Universitaetsspital Bern - Neuropsychologische Rehabilitation, Neurologie</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>robert.hoepner@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Robert Hoepner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(CHUV), Centre Hospitalier Universitaire Vaudois - Departement des Neurosciences Cliniques</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>marie.theaudin@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Marie Theaudin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano - Neurologia</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>claudio.gobbi@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Claudio Gobbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital - Zentrum fuer Neurologie und Neurorehabilitation</name>
      <address>
        <city>Luzern 16</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>christian.kamm@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Kamm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Régional Sion-Hérens-Conthey - Neurologie</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>christophe.bonvin@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Christophe Bonvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS700568_0070</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cladribine</keyword>
  <keyword>MAVENCLAD ®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

